Japan's Takeda committed to single-digit U.S. drug price rises

TOKYO (Reuters) - Japan's largest drugmaker, Takeda Pharmaceuticals Co, on Wednesday said it would maintain its pricing model in the U.S. market, brushing off demands by U.S. President Donald Trump for drugmakers to offer cheaper drugs.

Japan's Takeda committed to single-digit U.S. drug price rises
Read More


Bagikan Berita Ini